A previous study has indicated that MDSCs inhibit T cell responses in an indoleamine-2,3-dioxygenase (IDO)-dependent manner in CLL, and CLL-cells accelerate both the accumulation and activation of MDSCs. The gene discussed is IDO2; the disease is B-cell chronic lymphocytic leukemia.